Eli Lilly releases "promising" data for tirzepatide in fatty liver indication

Tirzepatide, which is the active ingredient in Eli Lilly’s blockbuster obesity drug Zepbound, perfomed well in a Phase II trial of fatty liver disease sufferers. 
Photo: Brendan Mcdermid
Photo: Brendan Mcdermid

Novo Nordisk rival Eli Lilly has been testing its active ingredient, tirzepatide, in new indications after its success on the diabetes and obesity markets. 

Already a subscriber?Log in here

Read the whole article

Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

With your free trial you get:

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
Must be at least 8 characters, including three of: Uppercase, lowercase, numbers, symbols
Must contain at least 2 characters
Must contain at least 2 characters

Get full access for you and your coworkers

Start a free company trial today

Share article

Sign up for our newsletter

Stay ahead of development by receiving our newsletter on the latest sector knowledge.

Newsletter terms

Front page now

Further reading